Related Experiment Video
Updated: Apr 16, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen1, Mika Aoyagi-Scharber2, Bing Wang2
1BioMarin Pharmaceutical Inc., Novato, California jshen@bmrn.com.
Abstract:
Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage. The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death. Several clinical-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity. Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells. In this article, we review the available data on molecular interactions between these clinical-stage PARP inhibitors and PARP proteins, and discuss how their biologic differences might be explained by the trapping mechanism. We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.
Insights
Poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells by trapping PARP1 and PARP2 to DNA damage sites. This trapping mechanism, not just catalytic inhibition, is key for effective cancer therapy development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising cancer therapy.
- A key mechanism of action involves trapping PARP1 and PARP2 at DNA damage sites.
Purpose of the Study:
- To review the molecular interactions of clinical PARP inhibitors with PARP proteins.
- To explain differences in drug efficacy through the PARP-trapping mechanism.
- To guide future development of PARP inhibitors in cancer treatment.
Main Methods:
- Review of existing data on molecular interactions.
- Analysis of PARP-trapping activity of clinical-stage inhibitors.
- Correlation of trapping ability with cancer cell killing.
Main Results:
- PARP inhibitors exhibit varying abilities to trap PARP, differing by orders of magnitude.
- PARP-trapping capacity strongly correlates with their efficacy in killing cancer cells.
- Inhibitor-PARP interactions explain observed biologic differences.
Conclusions:
- The PARP-trapping mechanism is crucial for the efficacy of PARP inhibitors.
- Understanding these molecular interactions can optimize PARP inhibitor development.
- PARP trapping offers a strategy for novel single-agent and combination cancer therapies.
Related Concept Videos
Restarting Stalled Replication Forks
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
Proofreading
Errors During Replication are Corrected by the DNA Polymerase...
Proofreading
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

